Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Reversing metabolic reprogramming in obesity-associated hepatocellular carcinoma by inhibiting receptor protein tyrosine phosphatases

Project description

A new targeting therapy for liver cancer

Obesity is a major risk factor for the development of hepatocellular carcinoma (HCC), which is the most common form of liver cancer and largely resistant to conventional chemotherapy. The ERC-funded REPRO-PTP project seeks to provide novel therapeutic options for HCC and other obesity-related liver diseases. The work will focus on specific enzymes that regulate glycolysis and lipogenesis and also contribute to HCC progression in obese patients. Researchers aim to develop and validate highly selective inhibitors for these enzymes and test their potency in animal models of the disease. Project findings could pave the way for alternative strategies for the treatment of HCC.

Objective

REPRO-PTP is addressing the critical need for effective treatments in obesity-associated hepatocellular carcinoma (HCC). HCC, which accounts for 90% of primary liver cancers, is refractory to conventional chemotherapy with very low survival rate. As obesity is a major risk factor for HCC, it is imperative to develop new therapeutic approaches. My laboratory has identified receptor protein tyrosine phosphatases (PTPs) as key regulators of glycolysis and lipogenesis, with PTPRK emerging as a particularly promising target. Mechanistically, PTPRK is selectively increased in tumorigenic hepatocytes, inactivating fructose-1,6-bisphosphatase 1 (FBP1) and promoting glycolysis. PTPRK-mediated glycolysis increases peroxisome proliferator-activated receptor (PPAR)γ-dependent lipogenic signalling and HCC progression in obesity. REPRO-PTP aims to optimize and validate new PTPRK inhibitors that exhibit high selectivity, potency, and in vivo activity. By targeting both hepatic glycolysis and lipogenesis, these inhibitors have the unique potential to improve treatment outcomes for HCC in obese patients by reducing cancer progression and relapse risk. We will provide a robust pipeline for the broader development of PTPRK and additional PTP inhibitors for translational applicability, devise an intellectual property strategy, and perform a commercial feasibility analysis. The project represents a collaborative effort involving experts in oncology, biochemistry, and pharmacology, and is expected to yield novel insights into PTPs as drug targets in cancer and metabolic diseases. REPRO-PTP aims to pave the way for the development of innovative therapies that can improve the quality of life and survival rates for patients suffering from HCC and potentially other obesity-related hepatic complications.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

UNIVERSITE LIBRE DE BRUXELLES
Net EU contribution
€ 150 000,00
Address
AVENUE FRANKLIN ROOSEVELT 50
1050 BRUXELLES
Belgium
Region
Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest Région de Bruxelles-Capitale/ Brussels Hoofdstedelijk Gewest Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)